



IK Partners

IK Partners and the Private Equity Reporting Group Guidelines

2024

Our Commitment



As a member of the British Private Equity and Venture Capital Association (“BVCA”), IK Investment Partners Limited (“IK Partners” or “IK”) is committed to providing data to the BVCA to enable it to conduct enhanced research into the private equity (“PE”) industry.

IK Partners has chosen to voluntarily comply with the Guidelines for Disclosure and Transparency in Private Equity (“the Guidelines”), published and overseen by the Private Equity Reporting Group (“PERG”), on a “comply or explain” basis. Furthermore, IK seeks to promote full conformity with the Guidelines, where relevant, on behalf of any of UK portfolio companies it owns that fall within the scope of the Guidelines.

Similar to its peers in the PE industry, IK Partners acknowledges that conflicts of interest may arise between the firm, its employees and its limited partners (“LPs”). Consequently, IK has developed policies and procedures to address these conflicts and has established systems and controls to effectively manage them. The Conflicts of Interest Policy implemented by IK is overseen by the Compliance team.

Leadership and History




IK Partners is a European private equity firm focused on investments in the Benelux, DACH, France, Nordics and the UK. Since 1989, IK has raised more than €14 billion of capital and invested in over 180 European companies. As of 31 December 2023, it had €8.7 billion in assets under management.

With seven offices across Europe, IK has a well-established presence with a team of approximately 190 employees, including over 100 investment professionals. The firm selectively deploys its funds in companies with strong potential for development in existing and international markets, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. IK invests across four core sectors: Business Services; Healthcare; Consumer; and Industrials.

The duration for which IK holds its investments is typically between four to six years. However, this may vary depending on specific factors, such as the circumstances of the company being considered for sale and prevailing market conditions at the time.

For more information, please visit the ['About Us'](#) section of our website.

The Structure of IK Investment Partners Limited



Ownership Structure

IK Investment Partners AIFM is a Fund Manager, regulated by the Commission de Surveillance du Secteur Financier (“CSSF”) in Luxembourg, acting for all Luxembourg-domiciled funds.

IK Investment Partners Ltd, regulated by the Financial Conduct Authority (“FCA”) in the United Kingdom, is the Fund Advisor and contracting entity with the regulated Fund Manager, IK Investment Partners AIFM. All funds currently within their investment period are Luxembourg resident, regulated and managed.



Governance of IK Investment Partners Limited

Christopher Masek (CEO), James Yates (CFO), Alice Langley (Partner, Investor Relations), Pete Wilson (Partner, Mid Cap) and Tom Salmon (Partner, Small Cap)

Investor Base



IK has a diverse range of LPs in terms of geography and type. With a razor-sharp focus on generating strong returns for all our stakeholders, we set rigorous standards for ourselves and are pleased to enjoy the continued commitment of many of our investors.



UK Investments



The following UK company is owned by funds managed by IK Investment Partners AIFM and falls within the enhanced disclosure requirements of the Guidelines:

medica:

IK Partners completed the acquisition of Medica Group (“Medica”) in July 2023 through a public-to-private transaction. Founded in 2004 and headquartered in Hastings, UK, Medica Group (“Medica” or the Group”) is a leading healthcare services provider in the UK, Ireland and US. Services offered include teleradiology, managed imaging services and imaging services for clinical trials.

For more information, visit <https://medica.co.uk/> or <https://ikpartners.com/investments/medica/>

